Edgewise Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDEdgewise Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings contraction of 7% provides fundamental context to the price action. Investors should exercise caution due to high volatility (70% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $32.91 | +8.12% | ABOVE |
| 50 SMA | $31.49 | +12.99% | ABOVE |
| 100 SMA | $29.25 | +21.63% | ABOVE |
| 150 SMA | $25.90 | +37.38% | ABOVE |
| 200 SMA | $23.03 | +54.47% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is EWTX in an uptrend right now?
EWTX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, EWTX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is EWTX overbought or oversold?
EWTX's RSI (14) is 66. The stock is in neutral territory, neither overbought nor oversold.
Is EWTX outperforming the market?
EWTX has a Relative Strength (RS) Rating of 89 out of 99. Yes, EWTX is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is EWTX in its 52-week range?
EWTX is trading at $35.58, which is 89% of its 52-week high ($39.96) and 84% above its 52-week low ($12.15).
How volatile is EWTX?
EWTX has a Beta of 1.09 and 52-week volatility of 70%. It's more volatile than the S&P 500 - expect bigger swings.